Highlights of the 2011 Scientific Sessions of the Congress of the Heart Failure Association of the European Society of Cardiology

Figures & data

Table 1. Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT): effect on primary and major secondary end points, ivabradine versus placebo.

Outcomes	Ivabradine n = 3241 (%)	Placebo n = 3264 (%)	HR (95% CI)	p-value
Primary end point
CV death or hospitalization for worsening heart failure	24	29	0.82 (0.75–0.90)	<0.0001
Secondary end points
All-cause death	16	17	0.90 (0.80–1.02)	0.092
CV mortality	14	15	0.91 (0.80–1.03)	0.128
Death from heart failure	3	5	0.74 (0.58–0.94)	0.014
All-cause hospital admission	38	42	0.89 (0.82–0.96)	0.003
Any cardiovascular hospital admission	30	34	0.85 (0.78–0.92)	0.0002
Hospitalization for worsening heart failure	16	21	0.74 (0.66–0.83)	<0.0001
CV death, HF hospitalization, or admission for nonfatal MI	25	30	0.82 (0.74–0.89)	<0.0001

CV: Cardiovascular; HF: Heart failure; HR: Hazard ratio; MI: Myocardial infarction.

Table 2. Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial: hazard ratio for cardiovascular death or heart failure hospitalization by quintiles of increasing baseline heart rate, relative to lowest quintile.

Baseline heart rate quintiles bpm	Hazard ratio (95% CI)	p-value
70 to <72	1.00	–
72 to <75	1.15 (0.88–1.48)	0.308
75 to <80	1.33 (1.03–1.70)	0.027
80 to <87	1.80 (1.40–2.31)	<0.0001
>87	2.34 (1.84–2.98)	<0.0001